Dysregulation of certain RTKs, especially insulin-like growth factor (IGF)-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), EGFR type 2 (HER2), and vascular endothelial growth factor (VEGF) receptor (VEGFR), are largely related to the acquisition of malignant hallmarks of tumor, as a result of which RTKs have become the most practical molecular targets for HCC therapy (Shimizu et al., 2011a; Park et al., 2022). Here, ERBB2 is linked to hepatocellular carcinoma.